Table 1 Comparison of the clinicopathologic factors and CTC status of adjuvant, salvage and adjuvant/salvage patient populations

From: The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy

 

Adjuvant, N (%)

Salvage, N (%)

Adjuvant/salvage, N (%)

Total, N (%)

Total

19 (34.5)

33 (60)

3 (5.5)

55 (100)

T stage

 T2

2 (11)

15 (45)

0 (0)

17 (31)

 T3a

15 (79)

14 (42)

3 (100)

32 (58)

 T3b

2 (11)

4 (12)

0 (0)

6 (11)

Gleason score

 6

1 (5)

6 (18)

0 (0)

7 (13)

 7

17 (89)

25 (76)

2 (67)

44 (80)

 8–10

1 (5)

2 (6)

1 (33)

4 (7)

Marginspos

12 (63)

17 (52)

2 (67)

31 (56)

ECEpos

17 (89)

18 (55)

3 (100)

38 (69)

SVIpos

2 (11)

5 (15)

1 (33)

8 (15)

CTCpos (baseline)

3 (16)

4 (12)

2 (67)

9 (16)

CTCpos (any time)a

5 (26)

9 (27)

2 (67)

16 (29)

  1. Abbreviations: CTC, circulating tumor cell; ECE, extracapsular extension; SVI, seminal vesicle invasion.
  2. aThe number of CTCs detected in patients within each patient population are as follows: 1 (n=4) and 3 (n=1) (adjuvant); 1 (n=6), 2 (n=1), 4 (n=1) and 5 (n=1) (salvage, with one patients having CTCs at baseline (4 CTCs) and 12 months (1 CTC)); 1 (n=1) and 2 (n=1) (adjuvant/salvage).
Back to article page